Viral protein Nef enables a step toward off-the-shelf CAR T cell therapy for cancer
CAR T cell therapy is one of the most promising new cancer treatments to emerge in recent years. It involves removing a ...
technologynetworks5d
Study Paves Way for Off-the-Shelf Cancer CAR T-Cell Therapy
The research identifies a way to modify the donor CAR T cells, called allogeneic CAR T cells, so that they won’t be rejected by the patient receiving them and will persist in fighting the cancer. The ...
GEN2d
Making Strides Toward Off-the-Shelf CAR T Cell Therapy for Cancer
A new advance may make it possible to use off-the-shelf CAR T cells provided by healthy donors. The new approach studied in mice equipped CAR T cells with the viral protein Nef.
Targeted Oncology13d
First Dose of CD38-Targeting CAR T-Cell Therapy Administered in AML
The first patient with relapsed/refractory acute myeloid leukemia has received KJ-C2320, an allogeneic CAR T-cell therapy ...
VectorBuilder Powers FDA IND Approval of World’s First Umbilical Cord Blood-Derived Allogeneic CAR-T Product
VectorBuilder's partner, Ucello, announced that its CD19-targeting umbilical cord blood-derived allogeneic CAR-T cell therapy ...
Health Rounds: Old anti-inflammatory may delay colon cancer recurrence
Patients with colon cancer who still have cancer cells in their blood after surgery may improve their survival odds with ...
Allogene Therapeutics Announces Participation in February Investor Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T ...
Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases
Best-in-Class Design to Enhance Therapeutic Benefit and Expand Treatment Potential Across a Range of Autoimmune Disease Indications; Inno ...
Medical Xpress5d
Viral protein Nef enables a step toward off-the-shelf CAR T cell therapy for cancer
The research identifies a way to modify the donor CAR T cells, called allogeneic CAR T cells, so that they won't be rejected by the patient receiving them and will persist in fighting the cancer.
Business Wire7d
VectorBuilder Powers FDA IND Approval of World’s First Umbilical Cord Blood-Derived Allogeneic CAR-T Product
CHICAGO--(BUSINESS WIRE)--VectorBuilder's partner, Ucello, announced that its CD19-targeting umbilical cord blood-derived allogeneic CAR-T cell therapy, UC101, received Investigational New Drug ...
Nasdaq8d
Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases
“Demonstrating the power of an allogeneic CAR T to reset the immune ... a pre-treatment regimen that may be a significant barrier to CAR T cell therapy adoption in autoimmune indications.
Morningstar8d
Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases
Dual-Targeted CD19/CD70 Allogeneic CAR T ... which leverages the clinically validated Dagger® technology to drive CAR T cell expansion and prevent rejection, includes two distinct lymphodepletion ...